MRD Focus: why measurable residual disease testing is the future
Bruno Paiva, Christoph Röllig, Christopher Hourigan, Gareth Morgan, Guillermo Garcia-Manero, Irene Ghobrial, Nikhil Munshi, Ola Landgren and Peter Hillmen
Measurable residual disease (MRD) testing has the potential to transform the landscape of disease prognosis and clinical decision-making in the field of hemato-oncology.
MRD describes the small number of cancer cells that still remain in patients that routine morphological detection does not detect. MRD testing is emerging as a benchmark prognostic indicator, which could potentially be used to improve patient outcomes.
MRD Focus is the new platform delivering the latest MRD updates to you, including a range of expert interviews, panel discussions, podcasts and interactive e-learning content.
Discover the latest advancements now at https://www.vjhemonc.com/field/mrd/
Get great new content delivered to your inboxSign up